Ensign Peak Advisors
PRME icon

Ensign Peak Advisors’s Prime Medicine PRME Stock Holding History

Ensign Peak Advisors’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-103,190
Closed -$530K – 1715
2024
Q2 		$530K Sell
103,190
-46,810
-31% -$284K ﹤0.01% 1586
2024
Q1 		$1.05M Hold
150,000
– – ﹤0.01% 1284
2023
Q4 		$1.33M Hold
150,000
– – ﹤0.01% 1169
2023
Q3 		$1.43M Hold
150,000
– – ﹤0.01% 951
2023
Q2 		$2.2M Hold
150,000
– – ﹤0.01% 836
2023
Q1 		$1.84M Hold
150,000
– – ﹤0.01% 881
2022
Q4 		$2.79M Buy
+150,000
New +$2.71M 0.01% 715

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Ensign Peak Advisors's PRME Position: Q3 2024 in Review

Ensign Peak Advisors sold out of Prime Medicine (PRME) in Q3 2024, closing a stake of 103,190 shares — an estimated $530K sold.

Ensign Peak Advisors first reported a position in PRME in Q4 2022 and held it in 7 quarters. The position peaked at $2.79M in Q4 2022. 116 funds tracked by Wall St. Rank hold PRME as of Q3 2024.

  • Ensign Peak Advisors reported no remaining Prime Medicine position as of Q3 2024 after selling out during the quarter.
  • Ensign Peak Advisors sold 103,190 Prime Medicine shares in Q3 2024, an estimated $530K.
  • Ensign Peak Advisors first reported a position in Prime Medicine in Q4 2022 and held it in 7 quarters.
  • Ensign Peak Advisors's Prime Medicine position peaked at $2.79M in Q4 2022.
  • 116 funds tracked by Wall St. Rank held Prime Medicine as of Q3 2024.

Based on Ensign Peak Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.